Working… Menu
Trial record 10 of 15 for:    Parachute

Safety Study of the Ventricular Partitioning Device (VPD) Implant System in Heart Failure Patients (PARACHUTE)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT00573560
Recruitment Status : Completed
First Posted : December 14, 2007
Last Update Posted : June 22, 2017
Information provided by (Responsible Party):
CardioKinetix, Inc

Brief Summary:
The CardioKinetix Ventricular Partitioning Device (VPD) is intended to isolate the malfunctioning portion of the left ventricle in patients with symptoms of heart failure due to ischemic heart disease. By isolating the malfunctioning portion of the left ventricle, it is hypothesized that the left ventricle will pump more effectively.

Condition or disease Intervention/treatment Phase
Heart Failure Device: VPD Implant System Phase 1

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 20 participants
Allocation: Non-Randomized
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: A Feasibility Trial to Evaluate the VPD Implant System - Percutaneous Ventricular Restoration in Chronic Heart Failure Due to Ischemic Heart Disease
Study Start Date : December 2007
Actual Primary Completion Date : January 2010
Actual Study Completion Date : June 2014

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Heart Failure

Intervention Details:
  • Device: VPD Implant System
    Percutaneous introduction using standard catheterization techniques of the VPD Implant.

Primary Outcome Measures :
  1. Assessment of safety defined as the successful delivery and deployment of the VPD Implant through 6 month follow up without the occurrence of Major Adverse Cardiac Events (MACE) related to the investigational device. [ Time Frame: 6 months ]

Secondary Outcome Measures :
  1. Preliminary Effectiveness Measurements at 6 months - Change in LV volume indices (LVESVI, LVEDVI, EF) - Change in 6 minute walk and VO2 max - Cardiovascular mortality and morbidity inclusive of hospitalization for HF, MI and stroke [ Time Frame: 12 months ]

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years to 74 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  1. Akinesis or dyskinesis due to myocardial infarction limited to anteroapical region
  2. Diagnosis of heart failure for a minimum of 6 months prior to enrollment
  3. NYHA Class at time of enrollment, either:

    • NYHA Class III or IV - if predominant during the 3-month period prior to enrollment
    • NYHA Class II - if diagnosed with NYHA Class III or IV during 3-month period prior to enrollment and ≥ 1 hospitalization for heart failure during 12-month period prior to enrollment
  4. LVEF ≤ 40% as measured by echocardiography
  5. Left ventricle must have appropriate anatomy as measured by Cardiac CT per the VPD Implant sizing criteria described in the device's Instructions For Use
  6. Eligible for cardiac surgery
  7. Between 18 and 74 years of age (inclusive)
  8. Receiving appropriate medical treatment for heart failure according to the ACC/AHA 2005 Guideline Update for the Diagnosis and Management of Chronic Heart Failure in the Adult during the three months prior to enrollment
  9. Female patients with childbearing potential must have a negative pregnancy test (within 7 days of the procedure) and must agree not to attempt to become pregnant during the course of the study
  10. Provide written informed consent
  11. Agree to the protocol-required follow-up

Exclusion Criteria:

  1. Myocardial ischemia requiring PCI or CABG
  2. Acute MI (see MI definition) within 60 days of enrollment or patients with suspected evolving MI at time of enrollment
  3. Cardiogenic shock within 72 hours of enrollment
  4. Revascularization procedure (PCI or CABG) within 60 days of enrollment
  5. Patient has received a CRT device within 60 days of enrollment
  6. Patient diagnosed with significant valve disease (AI >1+; MR >2+) which may or may not require surgery
  7. Patient has received an ICD within 60 days of enrollment
  8. Patient has received a pacemaker within 60 days of enrollment
  9. History of aborted sudden cardiac death, if patient has not received an ICD and has potentially lethal ventricular arrhythmia, VT or VF
  10. Patients with a history or a current diagnosis of either persistent or paroxysmal atrial fibrillation as well as patients who present with a contraindication to oral anticoagulant therapy
  11. Aortic valve replacement or repair
  12. Resting systolic blood pressure is more than 180 mmHg or less than 90 mmHg
  13. Resting heart rate more than 120 bpm
  14. Cardiac CT or echocardiographic evidence of thrombus in the left ventricle or left atrium
  15. History of bleeding diathesis or a major coagulopathy (i.e. platelet count < 100,000 plts/ml whole blood; PTT or PT > 1.3 times control value)
  16. GI bleed requiring transfusion within the past 3 months
  17. Patient has suffered a stroke within the past 6 months
  18. Evidence of severe calcification in the VPD Implant attachment zone
  19. Evidence of a significant sub-aortic obstruction ("left moderator band") in the area of implant
  20. History of Kawasaki's disease
  21. Patient has received a heart, lung, liver and/or kidney transplant
  22. Patient on dialysis or expected to require hemodialysis within 12 months
  23. Patient has chronic liver disease
  24. Patient has received intracardiac gene therapy or stem cell therapy
  25. Creatinine > 2.5mg/dl or impaired renal function that places patient at risk of contrast induced renal failure
  26. Hypersensitivity to contrast media
  27. Allergy or contraindication to clopidogrel or aspirin
  28. Evidence of ongoing infection (fever with temperature > 38°C and/or WBC > 15,000)
  29. Co-morbidities associated with a life expectancy of less than 12-months or there are factors making echo and clinical follow-up difficult (no permanent address, etc.)
  30. Patient is currently participating in another investigational device or drug research study for which the follow-up period is not complete

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT00573560

Layout table for location information
United States, District of Columbia
Washington Hospital Center
Washington, D.C., District of Columbia, United States, 20010
United States, Illinois
Northwestern University Medical Center
Chicago, Illinois, United States, 60611
United States, North Carolina
Mission Hospitals
Asheville, North Carolina, United States, 28802
United States, Ohio
The Ohio State University
Columbus, Ohio, United States, 43210
United States, Pennsylvania
Geisinger Medical Center
Danville, Pennsylvania, United States, 17822
United States, Texas
Texas Heart Institute
Houston, Texas, United States, 77030
Dedinje Cardiovascular Institute
Belgrade, Serbia, 11040
Sponsors and Collaborators
CardioKinetix, Inc
Layout table for investigator information
Principal Investigator: William T Abraham, MD Ohio State University
Publications automatically indexed to this study by Identifier (NCT Number):
Layout table for additonal information
Responsible Party: CardioKinetix, Inc Identifier: NCT00573560    
Other Study ID Numbers: US PARACHUTE Protocol
First Posted: December 14, 2007    Key Record Dates
Last Update Posted: June 22, 2017
Last Verified: July 2014
Keywords provided by CardioKinetix, Inc:
Heart failure
interventional cardiology
apical remodeling
LV dilatation
Additional relevant MeSH terms:
Layout table for MeSH terms
Heart Failure
Heart Diseases
Cardiovascular Diseases